NORWALK, Conn.--(BUSINESS WIRE)--The Food and Drug Administration’s (FDA) approach to drug safety is headed for significant changes in the wake of several high-profile drug withdrawals, critiques of the advisory committee process, and pending legislation to revamp its review procedures. These changes will have a lasting impact on the companies that develop and market regulated drugs. Steven E. Nissen, M.D., FACC, Vice-Chairman of Cardiology, The Cleveland Clinic Foundation, will headline an in-depth discussion of the changes underway and in consideration for the FDA’s drug evaluation and safety assessment procedures at Windhover’s FDA/CMS Summit.
